FDA panel backs BPC-157 compounding

The FDA's Pharmacy Compounding Advisory Committee (PCAC) voted on 23 July 2026 to recommend allowing compounding pharmacies to produce four unapproved peptides: BPC-157, KPV, TB-500, and MOTS-c.^[1] The recommendation is non-binding. The FDA will make the final determination on whether to add these peptides to the 503A bulk drug substances list, which governs what compounders may lawfully prepare for patients.

The vote was reported as narrow. STAT News noted that the majority of panelists who voted yes had financial ties to the peptide industry, a disclosure that accompanied the result.^[1] RFK Jr., the US Health and Human Services Secretary, had publicly advocated for opening the compounding pathway to peptides like BPC-157, framing the prior restrictions as agency overreach. The PCAC result was broadly characterised as a win for that position.

What the 503A pathway actually means

Under section 503A of the Food, Drug and Cosmetic Act, licensed compounding pharmacies can prepare individual patient prescriptions using bulk drug substances that appear on the FDA's approved list. Being on that list does not make a compound an approved drug. It means a compounder can lawfully prepare it for an individual prescription, subject to state pharmacy board oversight. BPC-157 and KPV currently sit outside that list, so compounders preparing them are doing so outside the legal framework, regardless of what they print on the vial.

The USADA confirmed this position directly: the FDA has stated that 'there is also no legal basis for compounding pharmacies to use BPC-157 in compounded medications.'^[2] A PCAC recommendation to add BPC-157 to the 503A list would change that legal picture for compounders, though it would not grant BPC-157 approved-drug status, which requires a successful new-drug application.

The evidence gap that the vote does not close

The core problem with BPC-157 is not regulatory; it is pharmacological. A 2026 review in Pharmaceutics (PMID 42198317) catalogued the translational barriers directly: fewer than 30 human subjects across three uncontrolled pilot studies, no pharmaceutical-grade formulation ever developed or validated, no established pharmacokinetic profile in people, and no preclinical toxicology meeting regulatory standards.^[3] The review's bottom line was blunt: 'The primary barrier to clinical translation is not the absence of biological activity, but the absence of fundamental pharmaceutical science.'

Eric Topol, in a July 2025 Substack piece on the broader peptide market, placed BPC-157 alongside other non-approved compounds and stated that 'there is no evidence from randomized trials in humans that any of these peptides provide the benefits that are advocated.' He also flagged the theoretical cancer-risk signal from BPC-157's angiogenic mechanism, specifically its promotion of VEGF expression and new blood vessel growth, as an area that warrants human data before wide clinical use.

None of that underlying evidence gap changes with the PCAC vote. If the FDA accepts the recommendation, compounders gain a lawful route to fill prescriptions. Patients and prescribers still face the same absence of controlled human trial data on dosing, safety, and long-term effects. The compounding pathway is a distribution question, not a clinical one. See the BPC-157 peptide page for a full breakdown of what the preclinical literature does and does not show.

What this is not

A drug approval. A clinical endorsement. Evidence that the rodent data translates to humans. And it is not yet FDA policy: the committee's recommendation now goes back to the agency, which can accept, modify, or decline it. The FDA has on previous occasions declined PCAC recommendations when the safety or efficacy picture was judged insufficient.

WADA's classification of BPC-157 under S0 (non-approved substances, banned in and out of competition) also does not change with a 503A listing. Athletes subject to the WADA Code who are prescribed compounded BPC-157 would still face sanction. USADA has stated no therapeutic use exemption is available for BPC-157 given its prohibited status.

Where this lands for readers tracking US compounding policy

The July 2026 PCAC vote is one step in a longer process. The FDA will now review the committee's recommendation, solicit public comment if required, and publish a final determination. The timeline for that determination is not fixed. Until the FDA publishes a final rule adding BPC-157 to the 503A list, the compounding restrictions remain in place. Per-country regulatory status on BPC-157 regulation is updated as official positions change.

The DoD's Operation Supplement Safety programme has characterised BPC-157 as an unapproved drug and warned active-duty service members against use.^[5] That framing reflects the FDA's pre-vote position. Whether the agency's final response to the PCAC recommendation shifts that framing is the thing to watch.

The KPV piece of the vote

KPV is a tripeptide fragment of alpha-melanocyte-stimulating hormone, abbreviated from its amino acid sequence: lysine, proline, valine. It is studied in preclinical models for anti-inflammatory and wound-healing properties. Like BPC-157, it has no marketing authorisation anywhere and no published controlled human efficacy trial. Its inclusion in the PCAC review alongside BPC-157 reflects the broader wave of non-approved peptides gaining visibility in the US wellness and sports-medicine markets.

Topol's 2025 Ground Truths piece grouped KPV with the wider category of non-approved peptides where advocacy outpaces evidence, noting that human trial data is absent across the class.^[4]

For readers following the adjacent ipamorelin compounding question, which the PCAC also reviewed in prior sessions, the regulatory logic is the same: a 503A listing creates a lawful prescription route, not an approval. The evidence bar for the underlying medicine remains wherever it was. Country-by-country detail on ipamorelin's regulatory status is on the ipamorelin peptide page.